Pardes Biosciences, Inc. Common Stock
PRDS
PRDS was delisted on the 30th of August, 2023.
1 hedge funds and large institutions have $66.7K invested in Pardes Biosciences, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 58 closing their positions.
98% less funds holding
Funds holding: 59 → 1 (-58)
100% less capital invested
Capital invested by funds: $63.9M → $66.7K (-$63.8M)
100% less funds holding in top 10
Funds holding in top 10: 5 → 0 (-5)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 58
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMV
Foresite Capital Management V
Larkspur,
California
|
-$19.6M |
| 2 |
VS
VK Services
Menlo Park,
California
|
-$11.1M |
| 3 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
-$7.06M |
| 4 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$6.86M |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
-$3.52M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Osaic Holdings
Scottsdale,
Arizona
| – | -$1.81K | -1,000 | Closed |
|
52
UBS Group
Zurich,
Switzerland
| – | -$614 | -339 | Closed |
|
53
New York State Common Retirement Fund
Albany,
New York
| – | -$543 | -300 | Closed |
|
|
SOW
54
State of Wyoming
Cheyenne,
Wyoming
| – | -$519 | -287 | Closed |
|
55
Nisa Investment Advisors
St. Louis,
Missouri
| – | -$340 | -188 | Closed |
|
56
Wells Fargo
San Francisco,
California
| – | -$273 | -151 | Closed |
|
57
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$266 | -147 | Closed |
|
58
Citigroup
New York
| – | -$221 | -122 | Closed |
|
59
Point72 Asset Management
Stamford,
Connecticut
| – | -$74 | -41 | Closed |
|
PRDS Hedge Fund Activity: Q3 2023 in Review
1 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Pardes Biosciences, Inc. Common Stock (PRDS) for Q3 2023, worth a combined $66.7K — down 100% from $63.9M a quarter earlier.
Sellers outnumbered buyers: 58 funds closed out of PRDS and 0 opened new positions — a net loss of 58 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was Foresite Capital Management V, exiting entirely with an estimated $19.6M sold.
- 1 institutional investor held Pardes Biosciences, Inc. Common Stock (PRDS) as of Q3 2023, down from 59 in Q2 2023.
- Funds reported $66.7K of Pardes Biosciences, Inc. Common Stock stock for Q3 2023, down 100% quarter-over-quarter.
- 0 funds opened new Pardes Biosciences, Inc. Common Stock positions in Q3 2023 and 58 closed out, a net change of -58 holders.
- The largest Pardes Biosciences, Inc. Common Stock seller in Q3 2023 was Foresite Capital Management V, an estimated $19.6M sold.
Based on aggregated 13F filings for Q3 2023.